Our rationale for using PC3 was that neuroendocrine carcinomas have worse prognoses than adenocarcinomas, and that they are insensitive to androgen ablation, making them appropriate for the clinical context of PARP‐1 inhibitor use.8, 9. Here, PARP1 is linked to neuroendocrine carcinoma.